Jianfei Tu

Dr. Jianfei Tu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
YBYanran Bi
Yanran Bi
XYXihui Ying
Xihui Ying
WCWanbin Chen
Wanbin Chen
JWJiahao Wu
Jiahao Wu
CKChunli Kong
Chunli Kong
JTJianfei Tu
Jianfei Tu
Metabolic reprogramming, a key mechanism regulating the growth and recurrence of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), still lacks effective clinical strategies for its integration into the precise screening of primary liver cancer. This study utilized ultra-high-performance liquid chromatography with quadrupole time-of-flight mass spectrometry to conduct a comprehensive, non-targeted metabolomics analysis, revealing significant upregulation of lipid metabolites such as phosphatidylcholine and lysophosphatidylcholine in patients with HCC and CCA, particularly within the glycerophospholipid metabolic pathway. Hematoxylin and eosin and immunohistochemical staining demonstrated marked upregulation of phospholipase A2 in tumor tissues, further emphasizing the potential of lipid metabolism as a therapeutic target and its important part in the course of cancer. This work provides a new viewpoint for addressing the clinical challenges associated with HCC and CCA, laying the groundwork for the broad application of early diagnosis and personalized treatment strategies, and ultimately aiming to provide tailored and precise therapeutic options for patients.

1 January 2024 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
DCDaxia Cai
Daxia Cai
FTFeng Tian
Feng Tian
MWMinhua Wu
Minhua Wu
JTJianfei Tu
Jianfei Tu
YWYonghui Wang
Yonghui Wang
The mechanism of action of UBE2C in lung adenocarcinoma (LUAD) and its significance in cancer diagnosis, targeted therapy and immunotherapy, even in pan-cancer, are still unclear. Several large public databases and online analysis tools were used for big data mining analysis. RNA interference technology, CCK8 assay, flow cytometry and apoptosis detection, and western blot were used for in vitro experiments. UBE2C was found to be overexpressed in various of tumors, including LUAD, and its expression level was found to be significantly related to gender, weight, tumor stage, grade and prognosis in LUAD. Downregulation of UBE2C expression induced proliferation suppression and G2/M phase arrest and cell apoptosis in LUAD cells and suppressed LUAD cell growth through inhibiting the Akt-mTOR signaling pathway. Expression level of UBE2C was negatively correlated with B cells and CD4+ T cell, and also with immune checkpoint genes in LUAD. Pan-cancer assay shown that UBE2C was significantly overexpressed in 28 cancers and was correlated with Ki-67 index in many cancers. Overexpression of UBE2C in BRCA, LUAD and MESO indicated worse Overall Survival (OS). UBE2C expression levels were positively associated with immunocyte infiltration, immune regulatory genes, immune checkpoints, TMB, MSI and MMRs in some cancers. Additionally, Single-cell functional analysis showed that UBE2C was positively correlated with cell cycle, proliferation, DNA damage, EMT, DNA repair, invasion and differentiation in some cancers. These findings suggested that UBE2C could be regarded as a latent diagnosis and prognostic biomarker and a new target for immunological therapy of cancers including LUAD.

3 February 2025 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
DCDa Xia Cai
Da Xia Cai
FTFeng Tian
Feng Tian
DZDeng Ke Zhang
Deng Ke Zhang
JTJianfei Tu
Jianfei Tu
YWYonghui Wang
Yonghui Wang
Objective: Overexpressed CRABP2 (Cellula Retinoi Aci Bindin Protei 2D) can promote progression of various tumors. However, there are few comprehensive analysis studies on CRABP2 in lung adenocarcinoma (LUAD).

9 August 2025 in Academic Radiology
Verified
Journal Article
Closed access
YFYe Feng
Ye Feng
YXYinuo Xu
Yinuo Xu
JWJian Wang
Jian Wang
ZCZhenyu Cao
Zhenyu Cao
BLBojun Liu
Bojun Liu
JTJianfei Tu
Jianfei Tu

18 June 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
DCDaxia Cai
Daxia Cai
JLJun Li
Jun Li
QCQiyi Chen
Qiyi Chen
XCXingdong Cai
Xingdong Cai
FTFeng Tian
Feng Tian
YWYonghui Wang
Yonghui Wang
Pulmonary sarcomatoid carcinoma (PSC) is frequently underdiagnosed or misdiagnosed due to its rarity and complex histological features. To date, no universally recommended treatment regimens have been established for this rare subtype, and clinical management is currently extrapolated primarily from standard non-small cell lung cancer (NSCLC) protocols. Herein, we report a case of PSC initially diagnosed as multiple primary lung cancer, including adenosquamous carcinoma and adenocarcinoma (pT1N0M0, IA stage, EGFR Exon-21 L858R mutation, below the detection limit) and adenocarcinoma (pT2aN0M0, stage IB, EGFR Exon-21 L858R mutation). Despite radical surgical resection followed by targeted therapy with afatinib (30 mg orally once daily), the disease recurred. Repeat biopsy confirmed the diagnosis of PSC secondary to histological transformation. The patient achieved a durable complete response (CR) to combined immunochemotherapy. We further review the existing literature on EGFR-TKI-associated histological transformation in lung cancer, to provide guidance for the clinical management of this challenging clinical scenario.

13 February 2025 in Clinical Radiology
Verified
Journal Article
Open access
JXjing xiang
jing xiang
WLW. Lan
W. Lan
DCD. Cai
D. Cai
YWY. Wang
Y. Wang
WLW. Li
W. Li
JHJ. Huang
J. Huang
Systemic chemotherapy plus immune checkpoint inhibitors (ICIs) are first-line treatment for advanced non-small cell lung cancer (NSCLC). However, elderly patients typically have comorbidities that tend to limit the use of chemotherapy at standard dosage and frequency. Drug-eluting bead bronchial arterial chemoembolisation (DEB-BACE)/bronchial arterial chemoembolization (BACE) represents options in such patients. This is a retrospective analysis. We screened all elderly patients (aged ≥70 years) undergoing treatment with immunotherapy plus DEB-BACE/BACE for pathologically confirmed stage III-IV NSCLC with negative driver gene mutations from October 2019 to December 2023 at our hospital. The response was evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1 criteria. The final analysis included 46 patients (median age: 76 years; 42 men and 4 women). Eastern Cooperative Oncology Group (ECOG) performance status was either 1 or 2. The median progression-free survival and overall survival were 9.1 months (95% confidence interval [CI]: 8.4-9.9) and 18.2 months (95% CI: 16.5-19.9), respectively, after a median follow-up of 20.3 months (95% CI: 19.5-21.1) in all populations. The most prevalent adverse events (AEs) were myelosuppression (76.1%, 35/46), followed by decreased appetite (71.7%, 33/46), nausea (65.2%, 30/46), and fatigue (54.3%, 25/46). The rate of any grade and grade ≥3 immune-related AEs was 34.8% (16/46) and 6.5% (3/46), respectively. No patients experienced treatment-related deaths, haemoptysis, or unexpected embolisation. DEB-BACE/BACE combined with immunotherapy was effective and well tolerated in elderly patients with advanced NSCLC.